Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	29.42B
Revenue (ttm)	5.99B
Net Income (ttm)	3.50B
Shares Out	770.09M
EPS (ttm)	4.54
PE Ratio	9.75
Forward PE	41.02
Dividend	1.28 (2.86%)
Ex-Dividend Date	Jul 4, 2025

Volume	13,784,064
Average Volume	8,478,239
Open	44.56
Previous Close	44.75
Day's Range	42.85 - 45.00
52-Week Range	26.16 - 46.00
Beta	0.86
RSI	70.82
Earnings Date	Aug 15, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.